Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.creatorDuarte, HO-
dc.creatorBalmaña, M-
dc.creatorMereiter, S-
dc.creatorOsório, H-
dc.creatorGomes, J-
dc.creatorReis, CA-
dc.description.abstractAberrant expression and hyperactivation of the human epidermal growth factor receptor 2 (ErbB2) constitute crucial molecular events underpinning gastric neoplastic transformation. Despite ErbB2 extracellular domain being a well-known target for glycosylation, its glycosylation profile and the molecular mechanisms through which it actively tunes tumorigenesis in gastric cancer (GC) cells remain elusive. We aimed at disclosing relevant ErbB2 glycan signatures and their functional impact on receptor's biology in GC cells. The transcriptomic profile of cancer-relevant glycosylation enzymes, and the expression and activation of the ErbB receptors were characterized in four GC cell lines. Cellular- and receptor-specific glycan profiling of ErbB2-overexpressing NCI-N87 cells unveiled a heterogeneous glycosylation pattern harboring the tumor-associated sialyl Lewis a (SLea) antigen. The expression of SLea and key enzymes integrating its biosynthetic pathway were strongly upregulated in this GC cell line. An association between the expression of ERBB2 and FUT3, a central gene in SLea biosynthesis, was disclosed in GC patients, further highlighting the crosstalk between ErbB2 and SLea expression. Moreover, cellular deglycosylation and CA 19.9 antibody-mediated blocking of SLea drastically altered ErbB2 expression and activation in NCI-N87 cells. Altogether, NCI-N87 cell line constitutes an appealing in vitro model to address glycan-mediated regulation of ErbB2 in GC.pt_PT
dc.description.sponsorshipThis work was funded by the project NORTE-01-0145-FEDER-000029, supported by Norte Portugal Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). This work was financed by FEDER—Fundo Europeu de Desenvolvimento Regional funds through COMPETE 2020—Operational Programme for Competitiveness and Internationalisation (POCI), Portugal 2020, and by Portuguese funds through FCT (Fundação para a Ciência e a Tecnologia)/Ministério da Ciência, Tecnologia e Inovação in the framework of the project “Institute for Research and Inovation in Health Sciences” (POCI-01-0145-FEDER-007274), the project POCI-01-0145-FEDER-016585 (PTDC/BBB EBI/0567/2014), and EU 7th framework programme ITN 316929. Mass spectrometry was performed at the Proteomics i3S Scientific Platform. Microscopy images were obtained at the Advance Light Microscopy i3S Scientific Platform. Henrique O. Duarte was supported by FCT through the FCT PhD Programmes and by Programa Operacional Potencial Humano (POPH), specifically by the BiotechHealth Programme (Doctoral Programme on Cellular and Molecular Biotechnology Applied to Health Sciences), with the reference PD/0016/2012 funded by FCT. Henrique O. Duarte received an individual grant (PD/BI/113948/2015) and a PhD studentship (PD/BD/128407/2017). Meritxell Balmaña has received a funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 748880.pt_PT
dc.relation.ispartofInternational journal of molecular sciences, vol. 18(11) p. E2262-
dc.subjectCA 19.9pt_PT
dc.subjectGastric cancerpt_PT
dc.subjectHuman epidermal growth factor receptor 2 (ErbB2)pt_PT
dc.subjectSialyl Lewis a (SLea)pt_PT
dc.titleGastric Cancer Cell Glycosylation as a Modulator of the ErbB2 Oncogenic Receptorpt_PT
dc.typeArtigo em Revista Científica Internacionalpt_PT
dc.contributor.uportoInstituto de Investigação e Inovação em Saúdept_PT
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
ijms18112262.pdf2.74 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons